Control of HIV across the WHO European region: progress and remaining challenges
- PMID: 40060938
- PMCID: PMC11889346
- DOI: 10.1016/j.lanepe.2025.101243
Control of HIV across the WHO European region: progress and remaining challenges
Abstract
Despite the ambitious global goal to control HIV transmissions by 2030, more than 30% of people with HIV from the WHO European Region show persistent transmissible levels of the virus. Successful introduction of oral pre-exposure prophylaxis (PrEP) has led to significant decreases in new HIV transmissions in some areas of Europe, particularly among men who have sex with men. However, the limited PrEP access or lack of state funding in many European countries underlines the need to increase efforts to make PrEP consistently and equitably available for all individuals in need. The success of modern antiretroviral therapy (ART) is evident throughout the WHO European region, with more than 90% of treated individuals with viral suppression. Remaining barriers to control HIV include disparities in access to testing facilities such as community-based centers, persistently high levels of late diagnosis, delayed linkage to care especially for undocumented migrant populations, and inequalities in access to treatment. Retention in care and maintenance of viral suppression are additional challenges. The ongoing war in Ukraine is causing service disruption for people with HIV. Combating HIV associated stigma and discrimination, particularly in Eastern Europe and Central Asia, seems paramount in removing barriers to testing; new testing strategies, such as emergency room opt-out testing, could enable earlier diagnosis of HIV in transmission groups that have been difficult to reach. This review summarizes the barriers, opportunities, and pathways towards improvement of the HIV response in the WHO European region.
Keywords: Ending AIDS; HIV; Migration; Stigma; Sustainable development goals.
© 2025 Published by Elsevier Ltd.
Conflict of interest statement
MP: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Gilead, Viiv/GSK, Janssen, Pfizer, MSD, Abbvie. JR: Consulting fees: Abbvie, Boehringer, MSD, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Gilead, Janssen, MSD, ViiV, Participation on a Data Safety Monitoring Board or Advisory Board: Berlin cures, Leadership or fiduciary role in other board, society, committee or advocacy group: EuroTEST Chair (unpaid). GK, SB, GC, MV AS, DG, JDA: No conflict of interest declared.
Figures


References
-
- United Nations (UN): New York The sustainable development goals. 2015. https://sdgs.un.org/goals Available at:
-
- UNAIDS . Joint United Nations Programme on HIV/AIDS; Geneva: 2021. Global AIDS Strategy 2021−2026: End Inequalities. End AIDS.https://www.unaids.org/resources/documents/2021/2021-2026-global-AIDS-st... Available at:
-
- European Centre for Disease Prevention and Control Progress towards reaching the sustainable development goals related to HIV in the European union and European economic area. Monitoring the implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia – 2023 progress report. 2024. https://www.ecdc.europa.eu/en/publications-data/evidence-brief-progress-... Available at:
-
- World Health Organization WHO global health observatory. https://www.who.int/data/gho Available at:
-
- European Centre for Disease Prevention Control . ECDC; Stockholm: 2024. Continuum of HIV Care. Monitoring Implementation of the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2023 Progress Report.https://www.ecdc.europa.eu/en/publications-data/hiv-continuum-care-monit... Available at:
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous